MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy
Whicker M, Lin Z, Sartorelli A, Ratner E. MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy. Gynecologic Oncology 2014, 133: 86-87. DOI: 10.1016/j.ygyno.2014.03.231.Peer-Reviewed Original Research